Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides

Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9448-52. doi: 10.1073/pnas.88.21.9448.

Abstract

The generation of antiviral cytotoxic T lymphocytes (CTLs) is a critical component of the immune response to viral infections. A safe and nontoxic vaccine for AIDS would optimally use a carrier-free synthetic peptide immunogen containing only components of HIV necessary for induction of protective immune responses. We report that hybrid synthetic peptides containing either a HIV envelope gp120 T-cell determinant (T1) or the envelope gp41 fusion domain (F) N-terminal to HIV CTL determinants are capable of priming murine CD8+, major histocompatibility complex class I-restricted anti-HIV CTLs in vivo. These data demonstrate that carrier-free, nonderivatized synthetic peptides can be used in vivo to induce anti-HIV CTL responses.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • CD8 Antigens / analysis
  • H-2 Antigens / immunology
  • HIV Antigens / chemistry*
  • HIV Envelope Protein gp120 / chemistry
  • HIV Envelope Protein gp120 / immunology*
  • HIV-1 / immunology*
  • Immunologic Memory
  • Major Histocompatibility Complex
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Molecular Sequence Data
  • Peptides / immunology*
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • CD8 Antigens
  • H-2 Antigens
  • HIV Antigens
  • HIV Envelope Protein gp120
  • Peptides